Clinical trial
Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects
NCT00418756 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00418756 |
|---|---|
| Title | Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects |
| Official title | A Phase I Open-label, Two Period, Single Center Study to Assess the Effect of 600 mg Daily Oral Dose of Rifampin (CYP3A4 Inducer) on the Pharmacokinetics of a Single 400 mg Oral Dose of Nilotinib in Healthy Subjects |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Nilotinib |
| Enrollment | 12 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2006 |
| First posted | Jan 5, 2007 |
| Last update posted | Mar 19, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: